STATUS
Built on our proprietary ImmTAX platform, we have a diverse pipeline of bispecific therapies across a broad range of indications.
Our pipeline includes clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects
Stage of Clinical Development
Candidate
Target (HLA type)
Indication
IND-enabling
Phase 1
Phase 2
Phase 3
Approved
Catalyst
Tebentafusp
gp100 (A02)
gp100 (A02)
Adjuvant uveal (ocular)
melanoma
Phase 3
Phase 3 Start | 2H 2024
2L+ advanced cutaneous melanoma
Phase 3
STATUS
Phase 3 enrollment completion | 1H 2026
Oncology
Brenetafusp
PRAME (A02)
PRAME (A02)
1L advanced cutaneous melanoma
Phase 3
STATUS
Phase 3 ongoing
PRAME (A02)
Cutaneous melanoma<sup>1</sup>
Phase 2
STATUS
2L+ Phase 1 Data | ASCO 2024
PRAME (A02)
Ovarian<sup>1, 2</sup>
Phase 2
STATUS
PRR<sup>2</sup> Phase 1 Data | ESMO 2024
PRAME (A02)
NSCLC<sup>1, 3</sup>
Phase 2
STATUS
2L+ Phase 1 Data | 4Q 2024
PRAME (A02)
Advanced endometrial<sup>1</sup>
Phase 2
STATUS
PRAME (A02)
Additional solid tumors<sup>1</sup>
Phase 2
STATUS
IMC-P115C
PRAME-HLE (A02)
PRAME-HLE (A02)
Multiple solid tumors
IND-enabling
STATUS
Phase 1 Start | 1H 2025
IMC-T119C
PRAME (A24)
PRAME (A24)
Multiple solid tumors
IND-enabling
STATUS
IND/CTA | 4Q 2024
IMC-R117C
PIWIL1 (A02)
PIWIL1 (A02)
Colorectal and GI cancers
Phase 1
STATUS
Phase 1 Start | 2H 2024
Infectious Diseases
IMC-M113V<sup>4</sup>
Gag (A02)
Gag (A02)
Human Immunodeficiency Virus (HIV)
Phase 1
STATUS
MAD Data | 1Q 2025
IMC-I109V
Envelope (A02)
Envelope (A02)
Hepatitis B Virus (HBV)
Phase 1
STATUS
Autoimmune Diseases
IMC-S118AI
PPIxPD1 (A02)
PPI (A02)
Type 1 Diabetes
IND-enabling
STATUS
Undisclosed
(universal)<sup>5</sup>
(universal)<sup>3</sup>
Dermatology
IND-enabling
STATUS
Date last updated: August 8, 2024
1 Phase 1/2 Monotherapy & Combinations. 2 Platinum refractory or resistant serous ovarian carcinoma. 3 NSCLC = Non-small cell lung cancer. 4 Program is wholly owned, development costs being provided by the Bill & Melinda Gates Foundation (BMGF), Immunocore retains all development and commercialization rights in the developed world. 5 Program is not HLA restricted (i.e. universal for all populations)
KIMMTRAK
KIMMTRAK approved for HLA-A*02:01–positive metastatic or unresectable uveal melanoma
Disclaimer
All trademarks, company and product names or logos are the property of their respective owners. The efficacy and safety of the molecules under investigation have not yet been established. There is no guarantee that pipeline molecules will receive approval and become commercially available for the uses being investigated as drug development is uncertain and agents in development may be terminated along the development process. The above information is accurate as of November 2023.